168
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Utilization of Antibiotics for Hospitalized Patients with Severe Coronavirus Disease 2019 in Al-Madinah Al-Munawara, Saudi Arabia: A Retrospective Study

ORCID Icon, , , , , , , , , , , , , , , , , & ORCID Icon show all
Pages 7401-7411 | Received 05 Sep 2022, Accepted 03 Nov 2022, Published online: 14 Dec 2022

References

  • European Centre for Disease Prevention and Control. Rapid risk assessment. Increased transmission of COVID-19 in the EU/EEA and the UK–thirteenth update; 2020. Available from: https://www.ecdc.europa.eu/en/publications-data/covid-19-risk-assessment-increased-transmission-thirteenth-update. Accessed June 24, 2022.
  • Beović B, Doušak M, Ferreira-Coimbra J, et al. Antibiotic use in patients with COVID-19: a ‘snapshot’Infectious Diseases International Research Initiative (ID-IRI) survey. J Antimicrob Chemother. 2020;75(11):3386–3390. doi:10.1093/jac/dkaa326
  • Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi:10.1016/S0140-6736(20)30566-3
  • Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of adverse events with antibiotic use in hospitalized patients. JAMA Intern Med. 2017;177(9):1308–1315. doi:10.1001/jamainternmed.2017.1938
  • Courtenay M, Castro-Sanchez E, Fitzpatrick M, Gallagher R, Lim R, Morris G. Tackling antimicrobial resistance 2019–2024–the UK’s five-year national action plan. J Hosp Infect. 2019;101(4):426–427. doi:10.1016/j.jhin.2019.02.019
  • Brundage JF, Shanks GD. Deaths from bacterial pneumonia during 1918–19 influenza pandemic. Emerg Infect Dis. 2008;14(8):1193. doi:10.3201/eid1408.071313
  • Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis. 2008;198(7):962–970. doi:10.1086/591708
  • Morris DE, Cleary DW, Clarke SC. Secondary bacterial infections associated with influenza pandemics. Front Microbiol. 2017;8:1041. doi:10.3389/fmicb.2017.01041
  • Feldman C, Anderson R. The role of co-infections and secondary infections in patients with COVID-19. Pneumonia. 2021;13(1):1–15. doi:10.1186/s41479-021-00083-w
  • Palacios G, Hornig M, Cisterna D, et al. Streptococcus pneumoniae coinfection is correlated with the severity of H1N1 pandemic influenza. PLoS One. 2009;4(12):e8540. doi:10.1371/journal.pone.0008540
  • Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5
  • Chen J. COVID-19 scientific advisory group rapid response report 2020. Alberta Health Services; May 6, 2020.
  • Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. Atlanta, GA: US Department of Health and Human Services; 2013. Available from: https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf. Accessed June 10, 2022.
  • Kwon WJ, Li G, Zheng M, Kaur H, Magbual N, Dalai S. Superinfections and coinfections in COVID-19–separating the signal from the noise. Medpage Today; 2020;28.
  • d’Humières C, Patrier J, Lortat-Jacob B, et al. Two original observations concerning bacterial infections in COVID-19 patients hospitalized in intensive care units during the first wave of the epidemic in France. PLoS One. 2021;16(4):e0250728. doi:10.1371/journal.pone.0250728
  • Rawson TM, Moore LSP, Castro-Sanchez E, et al. COVID-19 and the potential long-term impact on antimicrobial resistance. J Antimicrob Chemother. 2020;75(7):1681–1684. doi:10.1093/jac/dkaa194
  • Huttner BD, Catho G, Pano-Pardo JR, Pulcini C, Schouten J. COVID-19: don’t neglect antimicrobial stewardship principles! Clin Microbiol Infect. 2020;26(7):808–810. doi:10.1016/j.cmi.2020.04.024
  • MoH, Saudi. Protocol for Patients Suspected of/Confirmed with COVID-19 Supportive care and antiviral treatment of suspected or confirmed COVID-19 infection. Available from:https://www.moh.gov.sa/Ministry/MediaCenter/Publications/Documents/MOH-therapeutic-protocol. Accessed May 10, 2022.
  • Memish ZA, Shibl AM, Ahmed QAA; Group SAC-APW. Guidelines for the management of community-acquired pneumonia in Saudi Arabia: a model for the Middle East region. Int J Antimicrob Agents. 2002;20:S1–S12. doi:10.1016/S0924-8579(02)00243-1
  • Mustafa L, Tolaj I, Baftiu N, Fejza H. Use of antibiotics in COVID-19 ICU patients. J Infect Dev Ctries. 2021;15(4):501–505. doi:10.3855/jidc.14404
  • Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052–2059. doi:10.1001/jama.2020.6775
  • Instituto Superiore Di Sanita. COVID-19 surveillance group. Characteristics of COVID-19 patients dying in Italy: report based on available data on March 20th, 2020. Epidemiology for public health Istituto Superiore di Sanità; January 10, 2022. Available from: https://www.epicentro.iss.it/coronavirus/bollettino/Report-COVID-2019_20_marzo_eng.pdf. Accessed June 27, 2022.
  • Smati S, Tramunt B, Wargny M, et al. Relationship between obesity and severe COVID‐19 outcomes in patients with type 2 diabetes: results from the CORONADO study. Diabetes Obes Metab. 2021;23(2):391–403. doi:10.1111/dom.14228
  • Lighter J, Phillips M, Hochman S, et al. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. Clin Infect Dis. 2020;71(15):896–897. doi:10.1093/cid/ciaa415
  • Anderson MR, Geleris J, Anderson DR, et al. Body mass index and risk for intubation or death in SARS-CoV-2 infection: a retrospective cohort study. Ann Intern Med. 2020;173(10):782–790. doi:10.7326/M20-3214
  • Miranda C, Silva V, Capita R, Alonso-Calleja C, Igrejas G, Poeta P. Implications of antibiotics use during the COVID-19 pandemic: present and future. J Antimicrob Chemother. 2020;75(12):3413–3416. doi:10.1093/jac/dkaa350
  • Dudoignon E, Caméléna F, Deniau B, et al. Bacterial pneumonia in COVID-19 critically ill patients: a case series. Clin Infect Dis. 2021;72(5):905–906. doi:10.1093/cid/ciaa762
  • Metlay JP, Waterer GW. Treatment of community-acquired pneumonia during the coronavirus disease 2019 (COVID-19) pandemic. Ann Intern Med. 2020;173(4):304–305. doi:10.7326/M20-2189
  • Stevens MP, Patel PK, Nori P. Involving antimicrobial stewardship programs in COVID-19 response efforts: all hands on deck. Infect Control Hosp Epidemiol. 2020;41(6):744–745. doi:10.1017/ice.2020.69
  • Spernovasilis NA, Kofteridis DP. COVID-19 and antimicrobial stewardship: what is the interplay? Infect Control Hosp Epidemiol. 2021;42(3):378–379. doi:10.1017/ice.2020.246
  • Hughes S, Troise O, Donaldson H, Mughal N, Moore LSP. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clin Microbiol Infect. 2020;26(10):1395–1399. doi:10.1016/j.cmi.2020.06.025
  • Langford BJ, So M, Raybardhan S, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect s. 2020;26(12):1622–1629. doi:10.1016/j.cmi.2020.07.016
  • Echeverría-Esnal D, Martin-Ontiyuelo C, Navarrete-Rouco ME, et al. Azithromycin in the treatment of COVID-19: a review. Expert Rev Anti Infect Ther. 2021;19(2):147–163. doi:10.1080/14787210.2020.1813024
  • Parnham MJ, Erakovic Haber V, Giamarellos-Bourboulis EJ, Perletti G, Verleden GM, Vos R. Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacol Ther. 2014;143(2):225–245. doi:10.1016/j.pharmthera.2014.03.003
  • Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. 2020;323(24):2493–2502. doi:10.1001/jama.2020.8630
  • Shimizu T, Shimizu S. Azithromycin inhibits mucus hypersecretion from airway epithelial cells. Mediators Inflamm. 2012;2012:265714. doi:10.1155/2012/265714
  • Beigelman A, Mikols CL, Gunsten SP, Cannon CL, Brody SL, Walter MJ. Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis. Respir Res. 2010;11(1):90. doi:10.1186/1465-9921-11-90
  • Martínez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 2003;36(4):389–395. doi:10.1086/367541
  • Furtado RHM, Berwanger O, Fonseca HA, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet. 2020;396(10256):959–967. doi:10.1016/S0140-6736(20)31862-6
  • Wang X, Kattan MW. Cohort studies: design, analysis, and reporting. Chest. 2020;158(1S):S72–S78. doi:10.1016/j.chest.2020.03.014